Lilly Declares 2nd-Quarter 2021 Dividend and Announces Supplemental Share Repurchase Authorization

INDIANAPOLIS, May possibly 3, 2021 /PRNewswire/ — The board of administrators of Eli Lilly and Company (NYSE: LLY) (the “Board”) has declared a dividend for the 2nd quarter of 2021 of $.85 per share on outstanding typical stock. The dividend is payable on June 10, 2021 to shareholders of report at the near of enterprise on May 14, 2021.

The Board has also authorized the repurchase of up to an more $5 billion of the firm’s common inventory. This repurchase authorization is in addition to the authorization remaining less than the share repurchase system authorized by the Board in June 2018. As of March 31, 2021, there was $1 billion remaining below the 2018 share repurchase system.

Purchases may be produced from time to time at management’s discretion. The share repurchase authorizations allow shares to be repurchased in a variety of approaches, which include open market purchases, accelerated share repurchases, or other privately negotiated transactions. The share repurchase authorizations have no time limit and may perhaps be suspended or discontinued at any time.

About Eli Lilly and Company  
Lilly is a world wide wellness care chief that unites caring with discovery to generate medicines that make existence superior for people today all over the entire world. We ended up established extra than a century back by a male dedicated to building large-high-quality medicines that satisfy authentic wants, and today we remain accurate to that mission in all our get the job done. Throughout the globe, Lilly staff work to find out and bring lifetime-altering medicines to these who have to have them, boost the comprehending and administration of illness, and give again to communities as a result of philanthropy and volunteerism. To master more about Lilly, be sure to go to us at www.lilly.com and www.lilly.com/news. F-LLY

Lilly Cautionary Assertion Regarding Forward-Wanting Statements 
This push launch has ahead-hunting statements (as that time period is described in the Personal Securities Litigation Reform Act of 1995) related to predicted dividend payments and probable share repurchases and reflects Lilly’s present beliefs and anticipations. Nevertheless, there are considerable pitfalls and uncertainties in pharmaceutical study and growth, as effectively as in organization improvement actions and capital allocation techniques similar to the company’s business enterprise and precise final results may vary materially thanks to many components.  For a even more dialogue of these and other dangers and uncertainties that could bring about precise results to differ from Lilly’s expectations, be sure to see Lilly’s most the latest Types 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no responsibility to update forward-on the lookout statements.

Supply Eli Lilly and Company

Connected Links